You are here: Industry Insights > eczema

News List

US FDA approves drugs from AbbVie and Pfizer to treat eczema ExpressPharma
January 17, 2022
AbbVie’s Rinvoq and Pfizer’s Cibinqo have been approved to treat moderate-to-severe eczema, in patients who do not respond to previous treatment, or when use of other treatments is not recommended...
Amgen and Kyowa Kirin agree to jointly develop eczema med pharmatimes
June 02, 2021
Amgen and Kyowa Kirin have signed an agreement to jointly develop and commercialise KHK4083, a monoclonal antibody (mAb) in development for the treatment of atopic dermatitis – the most common form of eczema.
Lilly, Incyte tout new baricitinib data in eczema pharmatimes
November 05, 2020
Eli Lilly and Incyte showcased new data for their JAK inhibitor baricitinib in eczema at the virtual European Academy of Dermatology and Venereology (EADV) congress on Saturday.
Risk for Hodgkin Lymphoma Increased With Allergic Disease, Eczema drugs
December 18, 2019
The risk for Hodgkin lymphoma (HL) is increased in association with immunosuppression, allergic disease, and eczema, according to a study published online in the Journal of Allergy and Clinical Immunology.
Staphylococcus aureus Linked to Food Sensitization in Eczema drugs
June 05, 2019
Staphylococcus aureus Linked to Food Sensitization in Eczema.
Why Some Kids With Eczema Are at Higher Allergy Risk drugs
June 03, 2019
Why some kids with eczema are at higher allergy risk?
Eczema-Related School Absences Higher Among Blacks, Hispanics drugs
May 30, 2019
Eczema-Related School Absences Higher Among Blacks, Hispanics.
Dupixent's on a roll in eczema and asthma, but COPD's a ‘much tougher’ malady fiercepharma
May 09, 2019
Armed with new nods in asthma and adolescent eczema, Regeneron’s Dupixent keeps reeling in new biologics patients.
AAAAI: Exclusive Breastfeeding Not Linked to Eczema Risk drugs
February 26, 2019
Exclusive breastfeeding is not associated with the odds of general eczema diagnosis, but exclusive breastfeeding for three months or longer is associated with reduced odds of continued eczema at age 6.....
AOBiome Expands Receives Patent for Use of AOB for Eczema Treatment americanpharmaceuticalreview
January 03, 2019
AOBiome Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company's Ammonia Oxidizing Bacteria (AOB) for the treatment eczema....

Previous page 1 2 Next page